Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The clinical potential of interleukin-2.

Authors: M T Lotze; Y L Matory; A A Rayner; S E Ettinghausen; J T Vetto; C A Seipp; S A Rosenberg
Journal: Cancer Date: 1986-12-15 Impact factor: 6.860

7. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors: J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal: J Clin Oncol Date: 1987-03 Impact factor: 44.544

8. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

Authors: P J Cohen; M T Lotze; J R Roberts; S A Rosenberg; E S Jaffe
Journal: Am J Pathol Date: 1987-11 Impact factor: 4.307

9. Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.

Authors: M T Lotze; K Roberts; M C Custer; D A Segal; S A Rosenberg
Journal: J Surg Res Date: 1987-05 Impact factor: 2.192

10. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

Authors: A C Ochoa; G Gromo; B J Alter; P M Sondel; F H Bach
Journal: J Immunol Date: 1987-04-15 Impact factor: 5.422

4 in total

4. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Authors: J W Baars; C E Hack; J Wagstaff; A J Eerenberg-Belmer; G J Wolbink; L G Thijs; R J Strack van Schijndel; H L van der Vall; H M Pinedo
Journal: Br J Cancer Date: 1992-01 Impact factor: 7.640

4 in total

The clinical potential of interleukin-2.

1. Passive transfer of transplantation immunity.

2. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity.

3. On lymphokines, cytokines, and breakthroughs.

Review 4. Interleukin-2 (IL-2) and its receptor.

5. Immunotherapy of gastrointestinal cancer with monoclonal antibodies.

6. Clinical effects and toxicity of interleukin-2 in patients with cancer.

7. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

8. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

9. Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.

10. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

1. Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.

2. Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.

3. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.

4. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.